Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. Keeping that in mind, here are three value stocks with little support and some other investments you should consider instead.

Wendy's (WEN)

Forward P/E Ratio: 12.8x

Founded by Dave Thomas in 1969, Wendy’s (NASDAQ: WEN) is a renowned fast-food chain known for its fresh, never-frozen beef burgers, flavorful menu options, and commitment to quality.

Why Do We Steer Clear of WEN?

1. Lagging same-store sales over the past two years suggest it might have to change its pricing and marketing strategy to stimulate demand
2. Costs have risen faster than its revenue over the last year, causing its operating margin to decline by 3.4 percentage points

At $6.14 per share, Wendy's trades at 12.8x forward P/E. Check out our free in-depth research report to learn more about why WEN doesn’t pass our bar.

FOX (FOXA)

Forward P/E Ratio: 10.3x

Founded in 1915, Fox (NASDAQ: FOXA) is a diversified media company, operating prominent cable news, television broadcasting, and digital media platforms.

Why Should You Sell FOXA?

1. The company has faced growth challenges as its 5.8% annual revenue increases over the last five years fell short of other consumer discretionary companies
2. Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
3. Rising returns on capital show management is making relatively better investments

FOX is trading at $62.31 per share, or 10.3x forward P/E. To fully understand why you should be careful with FOXA, check out our full research report (it’s free).

Bristol-Myers Squibb (BMY)

Forward P/E Ratio: 9.5x

With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE: BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases.

Why Is BMY Not Exciting?

1. Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 2.1% over the last five years was below our standards for the healthcare sector
2. Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 8.2 percentage points
3. Performance over the past five years shows its incremental sales were less profitable as its earnings per share were flat

Bristol-Myers Squibb’s stock price of $61.05 implies a valuation ratio of 9.5x forward P/E. If you’re considering BMY for your portfolio, see our FREE research report to learn more.

Stocks We Like More

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.